Evaluating the Efficacy of Tocilizumab in Moderate to Severe COVID-19 with Progressive Illness despite Steroids: Identifying the Optimal Timing of its Administration in C3G study
Surabhi Madan, Manish Rana, Rohan Gajjar, Nitesh Shah, Vipul Thakkar, Bhagyesh Shah, Pradip Dabhi, Minesh Patel, Hardik Shah, Rashmi Chovatiya, Maulik Soni, Nirav Bapat, Amit Patel
doi: https://doi.org/10.1101/2020.11.07.20226837
Surabhi Madan
1Department of Infectious Diseases, Care Institute of Medical Sciences, Ahmedabad, India
Manish Rana
2Department of Community Medicine, GMERS Medical College, Sola, Ahmedabad, India
Rohan Gajjar
3Department of Clinical Research, Care Institute of Medical Sciences, Ahmedabad, India
Nitesh Shah
4Department of Pulmonary Medicine, Care Institute of Medical Sciences, Ahmedabad, India
Vipul Thakkar
5Department of Critical Care Medicine, Care Institute of Medical Sciences, Ahmedabad, India
Bhagyesh Shah
5Department of Critical Care Medicine, Care Institute of Medical Sciences, Ahmedabad, India
Pradip Dabhi
4Department of Pulmonary Medicine, Care Institute of Medical Sciences, Ahmedabad, India
Minesh Patel
5Department of Critical Care Medicine, Care Institute of Medical Sciences, Ahmedabad, India
Hardik Shah
9Department of Internal Medicine, Care Institute of Medical Sciences, Ahmedabad, India
Rashmi Chovatiya
9Department of Internal Medicine, Care Institute of Medical Sciences, Ahmedabad, India
Maulik Soni
4Department of Pulmonary Medicine, Care Institute of Medical Sciences, Ahmedabad, India
Nirav Bapat
2Department of Community Medicine, GMERS Medical College, Sola, Ahmedabad, India
Amit Patel
4Department of Pulmonary Medicine, Care Institute of Medical Sciences, Ahmedabad, India
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
No URL for external data sets or online supplementary material pertain to this manuscript.
Posted November 10, 2020.
Evaluating the Efficacy of Tocilizumab in Moderate to Severe COVID-19 with Progressive Illness despite Steroids: Identifying the Optimal Timing of its Administration in C3G study
Surabhi Madan, Manish Rana, Rohan Gajjar, Nitesh Shah, Vipul Thakkar, Bhagyesh Shah, Pradip Dabhi, Minesh Patel, Hardik Shah, Rashmi Chovatiya, Maulik Soni, Nirav Bapat, Amit Patel
medRxiv 2020.11.07.20226837; doi: https://doi.org/10.1101/2020.11.07.20226837
Evaluating the Efficacy of Tocilizumab in Moderate to Severe COVID-19 with Progressive Illness despite Steroids: Identifying the Optimal Timing of its Administration in C3G study
Surabhi Madan, Manish Rana, Rohan Gajjar, Nitesh Shah, Vipul Thakkar, Bhagyesh Shah, Pradip Dabhi, Minesh Patel, Hardik Shah, Rashmi Chovatiya, Maulik Soni, Nirav Bapat, Amit Patel
medRxiv 2020.11.07.20226837; doi: https://doi.org/10.1101/2020.11.07.20226837
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (671)
- Anesthesia (181)
- Cardiovascular Medicine (2656)
- Dermatology (224)
- Emergency Medicine (400)
- Epidemiology (12248)
- Forensic Medicine (10)
- Gastroenterology (763)
- Genetic and Genomic Medicine (4114)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2666)
- Health Policy (1005)
- Hematology (364)
- HIV/AIDS (853)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (439)
- Neurology (3897)
- Nursing (210)
- Nutrition (578)
- Oncology (2037)
- Ophthalmology (586)
- Orthopedics (241)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (452)
- Public and Global Health (6538)
- Radiology and Imaging (1407)
- Respiratory Medicine (871)
- Rheumatology (411)
- Sports Medicine (343)
- Surgery (451)
- Toxicology (53)
- Transplantation (185)
- Urology (166)